[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME [FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET COMPOSITIONS ET MÉTHODES DE TRAITEMENT ASSOCIÉES
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME [FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET COMPOSITIONS ET MÉTHODES DE TRAITEMENT ASSOCIÉES
Pyrazolesulfonamide derivative, process for its production and herbicide containing it
申请人:NISSAN CHEMICAL INDUSTRIES LTD.
公开号:EP0189069A2
公开(公告)日:1986-07-30
A pyrazolesulfonamide derivative represented by Formula (I):
wherein Q, m, R, B, D, E, W and G are as defined in the specification. The compound is useful as herbicide having not only an excellent killing effect on weeds but also the selectivity on certain crops. Useful processes for synthesizing the compound are also disclosed.
一种由式(I)表示的吡唑磺酰胺衍生物:其中 Q、m、R、B、D、E、W 和 G 如说明书中所定义。 该化合物可用作除草剂,不仅对杂草有很好的杀灭效果,而且对某些作物有选择性。 还公开了合成该化合物的有用工艺。
PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
申请人:An2H Discovery Limited
公开号:US20200317674A1
公开(公告)日:2020-10-08
The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R
21
, R
22
, R
23
, R
24
and R
25
are as defined herein.
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET COMPOSITIONS ET MÉTHODES DE TRAITEMENT ASSOCIÉES
申请人:AN2H DISCOVERY LTD
公开号:WO2017210678A1
公开(公告)日:2017-12-07
The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R21, R22, R23, R24 and R25 are as defined herein.